<DOC>
	<DOCNO>NCT02592408</DOCNO>
	<brief_summary>This randomize controlled trial ass efficacy safety national malaria treatment guideline , ass efficacy safety artesunate sulphadoxine - pyrimethamine ( AS+SP ) treatment uncomplicated P. falciparum P. vivax malaria hematologic effect 14 day routine primaquine base radical cure patient suffer P. vivax mixed infection .</brief_summary>
	<brief_title>A Study Assess Current Standard Malaria Treatment Guidelines Republic Sudan</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Artesunate</mesh_term>
	<mesh_term>Sulfadoxine</mesh_term>
	<mesh_term>Primaquine</mesh_term>
	<mesh_term>Pyrimethamine</mesh_term>
	<criteria>Age ≥ 12 month P. vivax P. falciparum monoinfection P. vivax / P. falciparum mixed infection Presence axillary temperature ≥ 37.5°C history fever past 24 hr Able tolerate oral medication Able willing comply study protocol duration study Informed consent patient parent guardian case child Bodyweight ≤5kg Presence general danger sign child age 5 year sign severe malaria patient accord definition WHO Presence severe malnutrition Acute anaemia &lt; 8g/dL Regular medication , may interfere antimalarial pharmacokinetics History hypersensitivity reaction contraindication drug ( ) test used alternative treatment ( ) A positive pregnancy test lactating .</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>